New Delhi News

The Relapsing Refractory Multiple Myeloma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Relapsing Refractory Multiple Myeloma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Relapsing Refractory Multiple Myeloma Market.

Some of the key takeaways from the Relapsing Refractory Multiple Myeloma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Relapsing Refractory Multiple Myeloma treatment therapies with a considerable amount of success over the years. 
• Relapsing Refractory Multiple Myeloma companies working in the treatment market are Artiva Biotherapeutics, Ionis Pharmaceuticals, MiNK Therapeutics, AbbVie, Ichnos Sciences, Sorrento Therapeutics, Alfa Takeda, Array BioPharma, Novartis, Gilead Sciences, Arcellx, Inc., Pfizer, Bristol-Myers Squibb, and others, are developing therapies for the Relapsing Refractory Multiple Myeloma treatment 

• Emerging Relapsing Refractory Multiple Myeloma therapies such as – AB-101, ION251, agenT-797, ABBV-383, ISB 1442, STI-6129, Modakafusp, Encorafenib, PHE885, Magrolimab, CART-ddBCMA, Elranatamab, Mezigdomide, and others are expected to have a significant impact on the Relapsing Refractory Multiple Myeloma market in the coming years. 
• In January 2023, Bristol-Myers Squibb initiated Phase III, two-stage, randomized, multicenter, open-labelstudy comparing CC-92480 (BMS-986348), carfilzomib, and dexamethasone (480Kd) versus carfilzomib and dexamethasone (Kd) in participants with Relapsed or Refractory Multiple Myeloma (RRMM). The trial is currently active with 525 participants and is estimated to get completed by February 2026 

Relapsing Refractory Multiple Myeloma Overview

A hematologic condition known as multiple myeloma (MM) is characterised by an overgrowth of malignant, monoclonal plasma cells in the bone marrow (BM) and/or extramedullary locations. When a patient receives treatment for multiple myeloma, but the malignancy recurs or does not react to the medication, this condition is known as relapsed refractory multiple myeloma (RRMM).

Get a Free Sample PDF Report to know more about Relapsing Refractory Multiple Myeloma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/relapsing-refractory-multiple-myeloma-pipeline-insight

Emerging Relapsing Refractory Multiple Myeloma Drugs Under Different Phases of Clinical Development Include:

• AB-101: Artiva Biotherapeutics
• ION251: Ionis Pharmaceuticals
• ORIC-533: ORIC Pharmaceuticals
• agenT-797: MiNK Therapeutics
• Iopofosine: Cellectar Biosciences, Inc.
• ABBV-383: AbbVie
• ISB 1442: Ichnos Sciences
• STI-6129: Sorrento Therapeutics
• Modakafusp: Alfa Takeda
• Encorafenib: Array BioPharma
• PHE885: Novartis
• Magrolimab: Gilead Sciences
• CART-ddBCMA: Arcellx, Inc.
• Elranatamab: Pfizer
• Mezigdomide: Bristol-Myers Squibb

Route of Administration

Relapsing Refractory Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

Relapsing Refractory Multiple Myeloma Pipeline Therapeutics Assessment

• Relapsing Refractory Multiple Myeloma Assessment by Product Type
• Relapsing Refractory Multiple Myeloma By Stage and Product Type
• Relapsing Refractory Multiple Myeloma Assessment by Route of Administration
• Relapsing Refractory Multiple Myeloma By Stage and Route of Administration
• Relapsing Refractory Multiple Myeloma Assessment by Molecule Type
• Relapsing Refractory Multiple Myeloma by Stage and Molecule Type

DelveInsight’s Relapsing Refractory Multiple Myeloma Report covers around 60+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Relapsing Refractory Multiple Myeloma product details are provided in the report. Download the Relapsing Refractory Multiple Myeloma pipeline report to learn more about the emerging Relapsing Refractory Multiple Myeloma therapies

Some of the key companies in the Relapsing Refractory Multiple Myeloma Therapeutics Market include:

Key companies developing therapies for Relapsing Refractory Multiple Myeloma are – Bristol-Myers Squibb, Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson), Amgen, Celgene (acquired by Bristol-Myers Squibb), Takeda Pharmaceutical Company, Novartis, GlaxoSmithKline, Merck & Co., AbbVie, Sanofi, Genentech, Onyx Pharmaceuticals (acquired by Amgen), Millennium Pharmaceuticals (acquired by Takeda), Karyopharm Therapeutics, Bluebird Bio, Poseida Therapeutics, CARsgen Therapeutics, Bellicum Pharmaceuticals, Cellectis, Gilead Sciences, and others.

Relapsing Refractory Multiple Myeloma Pipeline Analysis:

The Relapsing Refractory Multiple Myeloma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Relapsing Refractory Multiple Myeloma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Relapsing Refractory Multiple Myeloma Treatment.
• Relapsing Refractory Multiple Myeloma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Relapsing Refractory Multiple Myeloma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Relapsing Refractory Multiple Myeloma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Relapsing Refractory Multiple Myeloma drugs and therapies

Relapsing Refractory Multiple Myeloma Pipeline Market Drivers

• Players focusing on innovation of newer products and collaboration strategies • Increase in the prevalence of relapsed and refractory multiple myeloma, funding for the R&D activities from public and private sectors are some of the important factors that are fueling the Relapsing Refractory Multiple Myeloma Market.

Relapsing Refractory Multiple Myeloma Pipeline Market Barriers

• However, stringent regulations for product approval, adverse effects associated with the drugs and other factors are creating obstacles in the Relapsing Refractory Multiple Myeloma Market growth.

Scope of Relapsing Refractory Multiple Myeloma Pipeline Drug Insight    

• Coverage: Global
• Key Relapsing Refractory Multiple Myeloma Companies: Artiva Biotherapeutics, Ionis Pharmaceuticals, MiNK Therapeutics, AbbVie, Ichnos Sciences, Sorrento Therapeutics, Alfa Takeda, Array BioPharma, Novartis, Gilead Sciences, Arcellx, Inc., Pfizer, Bristol-Myers Squibb, and others
• Key Relapsing Refractory Multiple Myeloma Therapies: AB-101, ION251, agenT-797, ABBV-383, ISB 1442, STI-6129, Modakafusp, Encorafenib, PHE885, Magrolimab, CART-ddBCMA, Elranatamab, Mezigdomide, and others
• Relapsing Refractory Multiple Myeloma Therapeutic Assessment: Relapsing Refractory Multiple Myeloma current marketed and Relapsing Refractory Multiple Myeloma emerging therapies
• Relapsing Refractory Multiple Myeloma Market Dynamics: Relapsing Refractory Multiple Myeloma market drivers and Relapsing Refractory Multiple Myeloma market barriers 

Request for Sample PDF Report for Relapsing Refractory Multiple Myeloma Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services